Educational content only. Not medical advice, and no doctor-patient relationship is created. Read the medical disclaimer
OUR METHOD
Two questions for every peptide
Tier answers whether a peptide can lawfully be prescribed today. Grade answers how much to believe about it. We keep them separate because mixing them is how lawful products get oversold.
THE TIER
What we can lawfully do with each molecule
TIER 1
Prescribe today
FDA-approved, or lawfully compoundable now. This is the clinical offering and the only tier that appears on a service menu.
WHAT IT MEANS FOR YOU
You can discuss it at a consultation. A physician still decides whether it is right for you.
TIER 2
Prepare and watch
Removed from FDA’s safety-risk list and reviewed by its advisory committee, awaiting final rulemaking. We build protocols now.
WHAT IT MEANS FOR YOU
Not offered, and we will not imply that it is available until FDA acts.
TIER 3
Education only
Voted down, in litigation, investigational, or not supported by evidence. Teaching and advocacy material, nothing more.
WHAT IT MEANS FOR YOU
Not available through Youthful Medicine.
THE YOUTHFUL EVIDENCE GRADE
How much to believe
Grades describe the human evidence for the use being discussed. They are Dr. Tahir’s working assessments and are reviewed as new data appear.
A
Approved for this use
Multiple human randomized trials, and the indication being treated is the approved one.
EXAMPLE
Semaglutide for weight management
B
Strong evidence, different label
Well-conducted human trials support the use, but it is off-label or not yet approved.
EXAMPLE
Tesamorelin outside HIV lipodystrophy
C
Limited human evidence
Small trials, or strong mechanism with thin outcomes. Requires explicit consent and outcome tracking.
EXAMPLE
Sermorelin, LDN
D
Preclinical only
Animal or laboratory data. We will explain it at length, and we will not sell it.
EXAMPLE
MOTS-c, TB-500
X
We decline
Evidence contradicts the marketed claim, or a safety signal outweighs plausible benefit.
EXAMPLE
AOD-9604, Dihexa
REGULATION 101
How a peptide reaches a patient
There are three very different routes. Only two of them involve any oversight.
Sept 2023
FDA placed more than a dozen popular peptides, including BPC-157, on its Category 2 list of bulk substances that may present significant safety risks.
2024
FDA’s advisory committee reviewed ipamorelin, CJC-1295, AOD-9604 and thymosin alpha-1 and did not recommend them for compounding.
Apr 2026
Twelve peptides, including BPC-157, TB-500, MOTS-c and KPV, left Category 2 after their nominations were withdrawn. That did not make them compoundable.
Jul 2026
The advisory committee recommended BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A list in narrow votes, and voted against DSIP. FDA staff had recommended against all seven.
Next
FDA must decide whether to accept the votes, then publish a proposed rule, take public comment and issue a final rule. There is no fixed timeline.
Status summarized as of October 30, 2026. Regulations change; each library entry shows its own review date.
PROTECT YOURSELF
Red flags when you shop for peptides
Labels that say “research use only” or “not for human consumption”
No prescription, no physician visit and no lab work required
Dosing charts posted publicly for anyone to follow
No named, licensed U.S. pharmacy, or no certificate of analysis
Promises of rapid muscle gain or fat loss without lifestyle change
Claims that a peptide is “FDA approved” when only an advisory vote happened